Venetoclax treatment must be classified to add extra options for less fortunate patients of CLL.
From the letter of Mike Cheung, director and trustee, Cypress Charitable Trust Concerns are rising over Venetoclax treatment’s designation in the Hospital Authority Drug Formulary as a self-financed item not covered by the safety net. Venetoclax treatment is utilized for treating blood malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, most … Read more
